FDA Accepts sNDAs for Sarepta's PMO Drugs; PDUFA Set for Feb 2027

What happened

The FDA accepted for filing the sNDAs for AMONDYS 45 and VYONDYS 53, setting a PDUFA target date of February 28, 2027, to review the data from the failed ESSENCE confirmatory trial. While this procedural step keeps the drugs on a regulatory path, the DeepValue report underscores that the ESSENCE miss (p=0.309) leaves these accelerated approvals vulnerable to FDORA-enabled withdrawal. Sarepta itself warns that FDA actions could include label changes, revocation, or market removal, and the 8-month review window merely delays the binary decision. Critically, the acceptance does not de-risk the PMO franchise; it simply sets a defined timeline for a high-stakes judgment. Until the FDA's verdict, the bear case of a 30% probability and $10 implied value remains in play.

Implication

The FDA's acceptance buys time for Sarepta to negotiate a conversion path, but the bear case of 30% probability with value $10 remains. Investors should not interpret filing acceptance as de-risking; the PMO franchise remains under a cloud until the review concludes.

Thesis delta

This news shifts the PMO regulatory timeline from an acute near-term risk to a defined February 2027 decision point, marginally improving the odds of a managed outcome but not changing the fundamental binary risk. The thesis remains WAIT as the ELEVIDYS operational recovery is the more immediate driver.